Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists, Dietitians, PhDs, Physicians Assistants, Primary Care Physicians
Guidelines/Recommendations
| 1. | Compare and contrast approaches to lipid management for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol | 2. | Analyze the effectiveness of risk assessment approaches of the NLA's Recommendations for Patient-Centered Management of Dyslipidemia and the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
| 3. | Recognize differences in lipid management recommendations for special populations | 4. | Compare and contrast the role of lifestyle and pharmacologic therapies for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
| 1. | Compare and contrast approaches to lipid management for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
| 2. | Analyze the effectiveness of risk assessment approaches of the NLA's Recommendations for Patient-Centered Management of Dyslipidemia and the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
| 3. | Recognize differences in lipid management recommendations for special populations |
| 4. | Compare and contrast the role of lifestyle and pharmacologic therapies for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol |
CME credit provided by the National Lipid Association
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 4 contact hours (0.4 CEUs). UAN 0077-9999-15-007-H04-P. Initial Release Date: February 3, 2015.| FACULTY DISCLOSURES | ||
| NAME | RELATIONSHIP | COMPANY |
| Peter Jones, MD | Consultant | Amgen, Atherotech, Inc., Merck & Co., Inc., Sanofi-aventis/Regeneron Pharmaceuticals, Inc. |
| Speakers Bureau | Merck & Co., Inc. | |
| Pamela Morris, MD | Advisory Board | Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation |
| Speakers Bureau | Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation | |
| Carl Orringer, MD | Consultant | Merck & Co., Inc. |
| PLANNER DISCLOSURES | ||
| Robert Wild, MD, PhD, MPH (CME Reviewer) | Consultant | Atherotech, Inc. |
| AKH Staff/Planners | N/A | Nothing to Disclose |
| NLA Staff/Planners | N/A | Nothing to Disclose |
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |